Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

0.48

Mkt cap

4.2M

Volume

501K

High

0.53

P/E Ratio

-0.14

52-wk high

2.92

Low

0.46

Div yield

N/A

52-wk low

0.36

Enveric Biosciences has announced that a research article detailing the development of their lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be featured on the cover of the Journal of Medicinal Chemistry. This publication could signify a significant milestone for the company's research and development efforts in the field of psychedelic-inspired medicines.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 1:07 pm

Enveric Biosciences (NASDAQ:ENVB) reported a decrease in cash and cash equivalents and an increase in net loss for Q3 2023. The company is advancing its next-gen psychedelics, with significant IP developments and preclinical activities for its EVM301 series and EB-373 compound. Key milestones for the rest of 2023 include identifying a lead candidate for the EVM301 series and preparing for an IND application in 2024.

Portfolio Pulse from Lara Goldstein

November 14, 2023 | 7:52 pm

Enveric Biosciences (NASDAQ:ENVB) reported a narrower loss of $(1.30) per share in Q3, improving from a loss of $(1.46) per share in the same quarter last year, marking a 10.96% year-over-year improvement.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:29 pm

The article discusses various aspects of the psychedelics industry, including the potential of psychedelic treatments for PTSD in veterans, a possible $100M IPO by a psychedelics company, and Cybin Inc.'s new $64M offering. It also covers worldwide events related to psychedelics and provides a performance overview of the AdvisorShares Psychedelics ETF (PSIL) and several psychedelics stocks. Cybin Inc. announced an underwritten offering of units at $0.45, with $30M fully funded upon closing and an additional $34M upon full exercise of warrants. The article also lists the closing prices of several psychedelics stocks on November 10, with most showing a downward trend.

Portfolio Pulse from Lara Goldstein

November 13, 2023 | 1:39 am

California Senator Scott Wiener plans to introduce a revised bill next year to provide regulated therapeutic access to psychedelics, following Governor Gavin Newsom's veto of a broader legalization measure. The new bill, co-sponsored with Assemblymember Marie Waldron, will be crafted in response to Newsom's veto message, which called for regulated treatment guidelines before decriminalization. The bill will focus on providing access to regulated psychedelic therapies administered by licensed and vetted facilitators.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:22 pm

The U.S. Court of Appeals overruled the DEA's denial of a psilocybin rescheduling lawsuit. Psychedelics company Cybin Inc. shared positive Phase 2 study results for its psilocybin analog CYB003 on Major Depressive Disorder. Several states are discussing psychedelics reform. The AdvisorShares Psychedelics ETF (PSIL) showed a recovery in its weekly performance. Psychedelics stocks GH Research, COMPASS Pathways, Mind Medicine, Enveric Biosciences, Silo Pharma, Bright Minds Biosciences, Atai Life Sciences, Incannex Healthcare, FSD Pharma, and Cybin Inc. all closed at varying prices.

Portfolio Pulse from Lara Goldstein

November 07, 2023 | 12:02 am

Enveric Biosciences has entered into a purchase and registration rights agreement with Lincoln Park Capital Fund. Under the agreement, Lincoln Park has committed to purchase up to $10M of Enveric's common stock, as per an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:17 pm

A California campaign has withdrawn its proposed ballot initiative to create a $5 billion state agency for funding and promoting psychedelics research. The decision was influenced by recent polling showing 60% of likely California voters oppose state funding for psychedelic therapies. The campaign has announced the launch of a new TREAT Humanity campaign to explore mental health solutions more broadly. The proposed psychedelics institute would have identified opportunities for advancing scientific research into the therapeutic potential of psychedelics and facilitated the creation of 'care programs' for psilocybin and MDMA once approved for therapeutic use by the FDA.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 3:29 pm

Enveric Biosciences (NASDAQ:ENVB) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, a prodrug of psilocin being developed for the treatment of depression and anxiety disorders. The patent, titled 'C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,' includes claims for a family of novel prodrug derivatives of psilocin, including EB-373. The company has filed multiple patent applications for psilocin prodrugs and has submitted additional filings for companion Patent Cooperation Treaty and non-US national patent applications.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:12 pm

Psychedelics companies Cybin Inc. and Small Pharma Inc. have completed their acquisition agreement, making Small Pharma a wholly-owned subsidiary of Cybin. The combined company has received two patent grants from the USPTO and one from the European Patent Office. The AdvisorShares Psychedelics ETF has been showing a descending trend in its opening and closing prices. Other psychedelics stocks such as GH Research, COMPASS Pathways, Mind Medicine, Enveric Biosciences, Bright Minds Biosciences, Silo Pharma, Atai Life Sciences, Incannex Healthcare, FSD Pharma, and Cybin Inc. have also seen changes in their closing prices.

Portfolio Pulse from Lara Goldstein

October 30, 2023 | 2:48 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.